Click the blue text above to follow Alzheimer’s disease for free now
Preliminary results After confirming the safety of Cognito Therapeutics’ at-home gamma sensory stimulation device for Alzheimer’s disease (AD) patients, new data reveal more about the cognitive and functional benefits patients experience from this treatment /strong>. [1]
< p>
“NeurologyLive” April 14th
After 6 months of treatment, Patients receiving nontraumatic visual and auditory γ (40 Hz) sensory stimulation were assessed on the Alzheimer’s Disease Collaborative Study-Activity of Daily Living (ADCS-ADL) scale The change in score was significantly greater than in sham patients, indicating a 78% slowdown in cognitive decline (P < .0003). The findings, presented at the 2022 74th American Academy of Neurology (AAN) Annual Meeting, April 2-7 in Seattle, Washington, also showed the treatmentpotential disease-modifying effects, manifested in brain Reduced shrinkage.
Research presented at the 74th American Academy of Neurology (AAN) Annual Meeting in 2022
20
April 2-7, 2009
Lead author, Pediatric Neurology Specialist at Children’s Health Orange County Hospital, USA, M.D. Jonathan Megerian and colleagues screened 135 patients with AD, of which 74 were randomized and 53 completed the trial. Patients underwent physical and neurological examination, MRI, and efficacy outcomes were assessed using AD cognitive and functional instruments and volumetric MRI.
Dr.Jonathan Megerian score
except DLADCS-A Outside the placebo group, patients receiving γ sensory stimulation had a a statistically significant 83% reduction in cognitive decline (P < .013 ), expressed as a Mini Mental Status Exam (MMSE) score. There were no significant differences between the 2 treatment groups in other prognostic indicators such as AD Composite Score (MADCOMS), Alzheimer’s Disease Assessment Scale-14 (ADAS-Cog14) and Clinical Dementia Score Sum (CDR-SB).
Using quantitative MRI analysis, the researchers found that the active treatment group had a significant 72% reduction in brain atrophy compared to the sham treatment group (P < 0.01 ). In addition, lateral ventricle enlargement was reduced, occipital cortical thickness was reduced, and none of the patients exhibited any amyloid-related imaging abnormalities.
Similar to previously reported, gamma sensory stimulation showed safe profile, no unexpected serious treatment adverse events (AEs). Based on the raw data, subjects completed a total of 20,562 gamma sensory stimuli, with similar rates of AEs regardless of treatment (2.5 per subject) or sham treatment (2.5 per subject). [3]
Originally at the 2021 Alzheimer’s Association International Conference (AAIC) It was announced that the final mean compliance of the treatment group was 90.2% (±13.3), while the final mean compliance of the sham group was 90.2% (±9.0). No significant difference according to an independent two-tailed t-test(P = .14). When offered the opportunity to participate in the 12-month extension study, 60% of participants opted to participate.
In a sub-analysis of this trial, patients who received gamma sensory stimulation (n = 22) showed a significant reduction in nocturnal activity, conversely, at 24 weeks. During the treatment period, the sleep quality of the sham treatment group deteriorated (both P < .03). [2]
In a statement at the time, Cognito Therapeutics CEO Brent Vanaugh said, “The now reported improvement in nighttime sleep in patients with Alzheimer’s disease provides further support for mechanisms of disease amelioration in this patient population. This is an important milestone, and we look forward to working with Alzheimer’s disease Expand our clinical validation in pivotal studies in Zheimer’s disease.”[2]
References
Source: America n Academy of Neurology Annual Meeting
Gamma Sensory Stimulation Demonstrates Efficacy in Alzheimer Disease in New Analysis
References:
[1]. Megerian J, Hajos M, Hempel E, et al. Feasibility, safety, and efficacy of gamma sensory stimulation as a novel therapeutic intervention for Alzheimer disease. Presented at: 2022 AAN Annual Meeting; April 2-7; Seattle, Washington. Abstract 1936
[2]. Williams M, Cimenser A, Cotter C, et al. Safety, feasibility, and adherence of a daily, in-home gamma sensory stimulation therapy with the Cognito Sensory Stimulation System in Alzheimer’s subjects. Presented at 2021 AAIC Annual Meeting ; July 26-29. Abstract 268.
[3]. Cimenser A, Hempel E, Travers T, et al. Sensory-evoked 40-hz gamma oscillation improves sleep and daily activities in Alzheimer disease patients. Front Syst Neurosci. 2021;15:746859. doi:10.3389/fnsys.2021.746859
Disclaimer
This public The medical information on this website is provided and shared only as an information resource and is not intended for or relied upon for any diagnostic or therapeutic purpose. This information should not be used as a substitute for professional diagnosis or treatment. Please consult your doctor before making any medical decision or guidance regarding a specific medical condition.
Caring for Parents and Concerning “Alzheimer’s Disease”